examples, the linker polypeptide has at least 80% sequence identity to the sequence of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 or SEQ ID NO: 12. In some examples, the chimeric polypeptide has at least 80% sequence identity to the sequence of SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26 or SEQ ID NO: 28. In some examples, the chimeric polypeptide enhances, increases, augments, and/or supplements anchoring fibril formation, epithelial basement membrane organization, and/or epithelial basement adherence of a subject when the polypeptide is expressed in one or more target cells of the subject.

[0011a] In one aspect, the present disclosure refers to a pharmaceutical composition comprising: a) a replication-defective herpes simplex virus (HSV) comprising a recombinant herpes simplex virus genome, wherein the recombinant herpes simplex virus genome comprises one or more transgenes encoding a polypeptide selected from the group consisting of a Collagen alpha-1 (VII) chain polypeptide, a Lysyl hydroxylase 3 polypeptide, and a Keratin type I cytoskeletal 17 polypeptide; and b) a pharmaceutically acceptable carrier.

[0011b] In another example, the present disclosure refers to a pharmaceutical composition useful for delivery of one or more transgenes to the skin of a subject, comprising: a) a replication-defective herpes simplex virus (HSV) comprising a recombinant herpes simplex virus genome, wherein the recombinant herpes simplex virus genome comprises one or more polynucleotides encoding the one or more transgenes; and b) a pharmaceutically acceptable carrier; wherein the pharmaceutical composition is a topical, transdermal, subcutaneous, or intradermal composition; and wherein the replication-defective HSV is suitable for delivering the one or more polynucleotides encoding the one or more transgenes to one or more target cells of the epidermis and/or dermis of the subject.

[0012] Disclosed is a method of providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, the method comprising topically or transdermally administering a pharmaceutical composition capable of enhancing, increasing, augmenting, and/or supplementing the levels of a Collagen alpha-1 (VII) chain polypeptide and/or a Lysyl hydroxylase 3 polypeptide in one or more cells of the subject. In some examples, the pharmaceutical composition comprises a virus comprising a vector, wherein the vector comprises one or more transgenes encoding a Collagen alpha-1 (VII) chain polypeptide, a Lysyl hydroxylase 3 polypeptide, or a chimeric polypeptide thereof, and a pharmaceutically acceptable carrier. In some examples, the virus is an adenovirus, adeno-associated virus, retrovirus, lentivirus, sendai virus, herpes simplex virus, vaccinia virus, or any hybrid virus thereof. In some examples, the virus is replication-defective. In some examples, the virus is a herpes simplex virus (HSV). In some examples, the herpes simplex virus is a herpes simplex type 1 virus, a herpes simplex type 2 virus, or any derivatives thereof. In some examples, the herpes simplex virus comprises a modified envelope. In some examples, the modified envelope alters the herpes simplex virus tissue tropism relative to a wild-type herpes simplex virus. In some examples, the modified envelope comprises a mutant herpes simplex virus glycoprotein. In some examples, the vector is an HSV-1 amplicon or an HSV-1 hybrid amplicon. In some examples, the HSV-1 hybrid amplicon is an HSV/AAV hybrid amplicon, an HSV/EBV hybrid amplicon, and HSV/EBV/RV hybrid amplicon, or an HSV/*Sleeping Beauty* hybrid amplicon. In some examples, the vector is a recombinant herpes simplex virus genome. In some examples, the recombinant herpes simplex virus genome is a recombinant HSV-1 genome, a recombinant HSV-2 genome, or any derivatives thereof. In

CLAIMS

1. A pharmaceutical composition comprising:

    a) a replication-defective herpes simplex virus (HSV) comprising a recombinant herpes simplex virus genome, wherein the recombinant herpes simplex virus genome comprises one or more transgenes encoding a polypeptide selected from the group consisting of a Collagen alpha-1 (VII) chain polypeptide, a Lysyl hydroxylase 3 polypeptide, and a Keratin type I cytoskeletal 17 polypeptide; and

    b) a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1, wherein the recombinant herpes simplex virus genome comprises one or more transgenes encoding a Collagen alpha-1 (VII) chain polypeptide.

3. The pharmaceutical composition of claim 1 or claim 2, wherein the pharmaceutically acceptable carrier is suitable for a route of administration selected from the group consisting of topical administration, transdermal administration, subcutaneous administration, intradermal administration, and any combinations thereof.

4. The pharmaceutical composition of any one of claims 1-3, wherein the herpes simplex virus (HSV) is a herpes simplex type 1 virus or a herpes simplex type 2 virus.

5. The pharmaceutical composition of any one of claims 1-4, wherein the herpes simplex virus (HSV) is a herpes simplex type 1 virus (HSV-1).

6. The pharmaceutical composition of any one of claims 1-5, wherein the recombinant herpes simplex virus genome comprises an inactivating mutation.

7. The pharmaceutical composition of claim 6, wherein the inactivating mutation is in at least one herpes simplex virus gene selected from the group consisting of ICP0, ICP4, ICP22, ICP27, ICP47, tk, UL41, and UL55.

8. The pharmaceutical composition of any one of claims 1-7, wherein the recombinant herpes simplex virus genome comprises the one or more transgenes within one or more viral gene loci.

9. The pharmaceutical composition of any one of claims 1-8, wherein the recombinant herpes simplex virus genome comprises the one or more transgenes within one or more of the ICP4 viral gene loci.

10. The pharmaceutical composition of any one of claims 1-9, wherein the HSV has reduced cytotoxicity as compared to a wild-type herpes simplex virus.

11. The pharmaceutical composition of any one of claims 1-10 for use as a medicament.

12. The pharmaceutical composition of any one of claims 1-10 for use as a medicament to deliver the one or more transgenes to the skin of a subject.

13. The pharmaceutical composition of any one of claims 1-10 for use in providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin of a subject, wherein the subject suffers from epidermolysis bullosa.

14. Use of the pharmaceutical composition of any one of claims 1-10 in the manufacture of a medicament for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin of a subject, wherein the subject suffers from epidermolysis bullosa.

15. The pharmaceutical composition for use of claim 13, or the use of claim 14, wherein the pharmaceutical composition is to be administered topically, transdermally, subcutaneously, or intradermally to the subject.

16. The pharmaceutical composition for use of claim 13, or the use of claim 14, wherein the pharmaceutical composition is to be administered topically to the subject.

17. The pharmaceutical composition for use of claim 13, or the use of any one of claims 14-16, wherein the epidermolysis bullosa is dystrophic epidermolysis bullosa.

18. The pharmaceutical composition for use of claim 12 or claim 13, or the use of any one of claims 14-17, wherein the subject is a human.